Stevanato Group S.p.A.
NYSE:STVNMedical - Instruments & Supplies
+$0.67 today
- Market cap
- $4.20B
- Beta
- 0.78
- P/E (TTM)
- 29.9
- EPS (TTM)
- $0.52
- Dividend yield
- 0.35%
Volume 0.61M
Average 0.52M
STVN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Stevanato Group S.p.A.NYSE: STVN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of €64.29M rose 3.1% year over year, ahead of the -4.5% change in trailing-twelve-month EBITDA. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.
Context
- EBITDA amounted to 25.6% of revenue in FY2025, up 3.2 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of €343.46M (+17.6%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- €64.29M-1.2% QoQ
- Last fiscal yearDec 2025
- €292.01M+17.8% YoY
- LTMJun 2026
- €296.36M-4.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.1% | +16.8% | +13.8 pp |
| 1 year | +17.8% | +17.6% | -0.2 pp |
| 3-year CAGR | +4.4% | +17.0% | +12.6 pp |
| 5-year CAGR | +20.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- 292.01M EUR
- Year-over-year change
- +17.8%
- 4-year CAGR
- +6.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 292.01M | +17.8% |
| FY2024 | 2024-12-31 | 247.8M | -9.0% |
| FY2023 | 2023-12-31 | 272.35M | +6.2% |
| FY2022 | 2022-12-31 | 256.4M | +13.0% |
| FY2021 | 2021-12-31 | 226.93M | — |
EBITDA vs competitors
How STVN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.5% is the 7th highest of 11, against a peer median of +5.3%.
- EBITDA amounts to 24.3% of revenue for STVN, versus a peer median of 16.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $822.22M USD | +1.7% | +10.9% | 20.9% | |
| LTM Jun 2026 | $742M USD | +61.3% | -3.6% | 13.9% | |
| LTM Sep 2026 | $709.15M USD | +59.1% | +5.5% | 4.6% | |
| LTM Jun 2026 | $431.72M USD | -4.8% | +2.4% | 16.6% | |
| LTM Apr 2026 | $344.5M USD | +414.9% | -1.0% | 22.1% | |
| LTM Sep 2026 | $341.34M USD | +9.0% | +22.4% | 21.2% | |
| LTM Jun 2026 | €296.36M EUR | -4.5% | +4.4% | 24.3% | |
| LTM Jun 2026 | $125.3M USD | -91.1% | -55.0% | 1.9% | |
| LTM Jun 2026 | -$158.49M USD | -126.4% | -25.5% | 6.1% | |
| LTM Jun 2026 | -$176.13M USD | +22.9% | — | 22.7% | |
| LTM Mar 2026 | -$334.38M USD | -11.3% | — | — | |
| Peer median (excluding STVN) | — | +5.3% | +0.7% | 16.6% | |
Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 843.92M | 983.68M | 1.09B | 1.1B | 1.14B |
| Cost of Revenue | 578.52M | 663.88M | 745.46M | 801.72M | 809.15M |
| Gross Profit | 265.41M | 319.8M | 339.89M | 302.32M | 330.33M |
| Gross Margin | 31.4% | 32.5% | 31.3% | 27.4% | 29.0% |
| Research & Development | 29.62M | 34.39M | 35.67M | 31.67M | 24.4M |
| Selling, General & Admin | 82.95M | 111.83M | 113.92M | 118.6M | 122.85M |
| Operating Expenses | 103.18M | 127.37M | 139.17M | 141.18M | 147.25M |
| Depreciation & Amortization | 56.38M | 64.82M | 78.48M | 80.65M | 88.57M |
| EBITDA | 226.93M | 256.4M | 272.35M | 247.8M | 292.01M |
| EBITDA Margin | 26.9% | 26.1% | 25.1% | 22.4% | 25.6% |
| Operating Income | 162.23M | 192.43M | 200.72M | 161.14M | 183.08M |
| Operating Margin | 19.2% | 19.6% | 18.5% | 14.6% | 16.1% |
| Interest Income | 548K | 648K | 792K | 1.72M | 12.49M |
| Interest Expense | 4.87M | 3.94M | 4.32M | 6.86M | 21.8M |
| Other Income / Expenses | 3.45M | (4.79M) | (11.17M) | (854K) | (1.44M) |
| Income Before Tax | 165.67M | 187.64M | 189.55M | 160.29M | 181.64M |
| Pre-Tax Margin | 19.6% | 19.1% | 17.5% | 14.5% | 15.9% |
| Income Tax Expense | 31.4M | 44.63M | 43.86M | 42.52M | 47.35M |
| Net Income | 134.32M | 142.85M | 145.63M | 117.78M | 134.28M |
| Net Margin | 15.9% | 14.5% | 13.4% | 10.7% | 11.8% |
| EPS (Basic) | 0.53 | 0.53 | 0.55 | 0.43 | 0.49 |
| EPS (Diluted) | 0.53 | 0.53 | 0.55 | 0.43 | 0.49 |
| Weighted Avg Shares | 264.7M | 264.7M | 264.95M | 272.87M | 273M |
| Weighted Avg Shares (Diluted) | 264.7M | 264.7M | 264.98M | 272.88M | 273M |
Stevanato Group S.p.A.
NYSE:STVN
Intrinsic Alpha fair value
Locked
Current Price
$15.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.